2000
HTLV-II and Bacterial Infections Among Injection Drug Users
Safaeian M, Wilson L, Taylor E, Thomas D, Vlahov D. HTLV-II and Bacterial Infections Among Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 24: 483-487. DOI: 10.1097/00042560-200008150-00014.Peer-Reviewed Original ResearchConceptsHTLV-II infectionInjection drug usersHTLV-IIBacterial pneumoniaInfective endocarditisOdds ratioBacterial infectionsDrug usersChart reviewConditional logistic regression methodsSelf-reported skinStandardized chart reviewOngoing cohort studyCase-control studyEnzyme-linked immunosorbentCohort studyHIV statusResults PrevalenceSkin abscessesRisk factorsControl studyEndocarditisInfectionImmunofluorescent assayPneumonia
1998
HIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore
Zhang H, Flynn C, Nelson K, Chen W, Kawalski R, Vlahov D. HIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 397-398. PMID: 9704951, DOI: 10.1097/00042560-199808010-00018.Peer-Reviewed Original Research
1996
An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users
Hershow R, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein R, Jarlais D, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, Kaplan J. An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users. The Journal Of Infectious Diseases 1996, 174: 309-317. PMID: 8699060, DOI: 10.1093/infdis/174.2.309.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell percentCell percentHuman immunodeficiency virus type 1 (HIV-1) disease progressionHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersInfected injection drug usersVirus type 1 infectionHuman T-lymphotropic virus type IIHIV seroconversion datesHTLV-II infectionType 1 infectionProportional hazards modelEffect of coinfectionSeroconversion datesCohort studyHIV infectionHTLV infectionDisease progressionAIDS mortalityHTLV-IIHazards modelRate of declineInternational collaborative studyWestern blot
1995
Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A
Vlahov D, Khabbaz R, Cohn S, Galai N, Taylor E, Kaplan J. Incidence and Risk Factors for Human T-Lymphotropic Virus Type II Seroconversion Among Injecting Drug Users in Baltimore, Maryland, U.S.A. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 9: 89-96. PMID: 7712239, DOI: 10.1097/00042560-199505010-00013.Peer-Reviewed Original ResearchConceptsRisk factorsDrug usersEnzyme immunoassayWestern blotHuman T-lymphotropic virusNeedle-sharing practicesRisk factor analysisT-lymphotropic virusMedian lag timeCase-control designALIVE studyRecent serumSeronegative IDUsStudy entryBaseline historyIncidence rateSeroconversionPositive casesSex partnersIDUsHTLVCalendar timeMonthsIncidenceBaseline
1994
Improved Detection of HTLV-II Antibody Using a Whole Viral Lysate-Based EIA
Kline R, Vlahov D, Quinn T. Improved Detection of HTLV-II Antibody Using a Whole Viral Lysate-Based EIA. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1994, 7: 1291. PMID: 7965644, DOI: 10.1097/00126334-199412000-00016.Peer-Reviewed Original Research
1991
Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.
Viscidi R, Hill P, Li S, Cerny E, Vlahov D, Farzadegan H, Halsey N, Kelen G, Quinn T. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 1190-8. PMID: 1941526.Peer-Reviewed Original ResearchConceptsEnzyme immunoassayHTLV-IIAntibody reactivityPeptide enzyme immunoassayHTLV-II infectionEpidemiology of HTLVDifferentiation of HTLVMicrotiter plate enzyme immunoassaysPattern of reactivitySeronegative controlsEmergency departmentEnv peptidesPositive seraViral infectionNeurological diseasesHTLVSynthetic peptidesInfectionDrug abuseMajor envelope proteinEnvEnvelope proteinPatientsSerumAntibodies